Related Experiment Videos
Brain single photon emission computed tomography: newer activation and intervention studies.
1Department of Radiology, Medical College of Wisconsin, Milwaukee.
Seminars in Nuclear Medicine
|January 1, 1991
Summary
Single-photon emission computed tomography (SPECT) using non-xenon 133 tracers can detect changes in regional cerebral blood flow (rCBF) during interventions. Further development is needed, but SPECT shows promise for distinguishing normal and diseased brain states.
Area of Science:
- Neuroimaging
- Nuclear Medicine
- Radiochemistry
Background:
- Regional cerebral blood flow (rCBF) is a key indicator of brain function.
- Single-photon emission computed tomography (SPECT) is a valuable neuroimaging technique.
- Non-xenon 133 tracers offer an alternative for SPECT rCBF studies.
Purpose of the Study:
- To review SPECT rCBF findings using non-xenon 133 tracers.
- To assess the utility of these tracers in activation and intervention studies.
- To evaluate the potential of SPECT for differentiating normal and pathological brain states.
Main Methods:
- Review of existing literature on SPECT rCBF studies.
- Analysis of data from studies employing non-xenon 133 tracers.
- Comparison with established techniques like xenon 133 and positron emission tomography (PET).
Main Results:
- SPECT rCBF with non-xenon 133 tracers can detect effects of various activation and intervention procedures.
- Current SPECT technology requires further refinement to match xenon 133 and PET sophistication.
- Research indicates significant potential for SPECT to improve differentiation between normal and pathological conditions.
Conclusions:
- SPECT rCBF using non-xenon 133 tracers is a viable method for studying brain activity.
- Continued research and development are crucial for optimizing SPECT's role in neuroimaging.
- SPECT holds promise for enhanced clinical applications in diagnosing and monitoring neurological disorders.